Barrier Therapeutics

Although Alnylam Pharmaceuticals Inc. 's recent safety crisis with Phase III candidate revusiran suggests that RNA interference therapies remain a long way from the market, RXi Pharmaceuticals Co

Venerable corporate venture arm strengthening ties—and aligning strategy—with corporation’s many different parts by Tom Salemi Despite Johnson & Johnson Development Corp.’s strong reputation as a vent

VCs—particularly those in Europe—love pre-cooked start-ups and one of the best places to find them is within Big Pharma. So it wasn’t that surprising to see Belgium-based Movetis NV raise a record €

Spin-outs tend to raise more money privately than their build-from-scratch brethren, and in Europe are seen as one of the few sustainable biotechnology business models. (See "Are Spin-Outs Really a B